3:40 PM
 | 
Sep 13, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

BMS's IPF therapy discontinued after Phase II safety signal

Data published in Chest showed that a twice-daily 600 mg dose of BMS-986020 from Bristol-Myers Squibb Co. (NYSE:BMY) significantly slowed the rate of decline in forced vital capacity (FVC) vs. placebo in the Phase II IM136003 trial to treat idiopathic pulmonary fibrosis (IPF), but the trial was terminated for safety reasons.

The published data showed that in 108 evaluable patients with IPF, those...

Read the full 295 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >